Mersana Therapeutics Announces Partial Clinical Hold On UP-NEXT And UPGRADE-A Clinical Trials
Portfolio Pulse from Benzinga Newsdesk
Mersana Therapeutics has announced a partial clinical hold on its UP-NEXT and UPGRADE-A clinical trials. The hold is due to safety concerns raised by the FDA, which requires additional information before allowing the trials to proceed.
June 15, 2023 | 11:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mersana Therapeutics' stock may be negatively impacted by the partial clinical hold on its UP-NEXT and UPGRADE-A clinical trials due to FDA safety concerns.
The partial clinical hold on Mersana Therapeutics' UP-NEXT and UPGRADE-A clinical trials is a significant setback for the company. The FDA's safety concerns may delay the trials' progress, which could negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100